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Abstract
Background: Matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), and
urokinase-type plasminogen activator (uPA) are involved in colorectal cancer invasion and
metastasis. There is still debate whether the activity of MMP-2 and MMP-9 differs between tumors
located in the colon and rectum. We designed this study to determine any differences in the
expression of MMP-2, MMP-9 and uPA system between colon and rectal cancer tissues.
Methods:  Cancer tissue samples were obtained from colon carcinoma (n = 12) and rectal
carcinomas (n = 10). MMP-2 and MMP-9 levels were examined using gelatin zymography and
Western blotting; their endogenous inhibitors, tissue inhibitor of metalloproteinase-2 (TIMP-2) and
tissue inhibitor of metalloproteinase-1 (TIMP-1), were assessed by Western blotting. uPA, uPAR
and PAI-1 were examined using enzyme-linked immunosorbent assay (ELISA). The activity of uPA
was assessed by casein-plasminogen zymography.
Results: In both colon and rectal tumors, MMP-2, MMP-9 and TIMP-1 protein levels were higher
than in corresponding paired normal mucosa, while TIMP-2 level in tumors was significantly lower
than in normal mucosa. The enzyme activities or protein levels of MMP-2, MMP-9 and their
endogenous inhibitors did not reach a statistically significant difference between colon and rectal
cancer compared with their normal mucosa. In rectal tumors, there was an increased activity of
uPA compared with the activity in colon tumors (P = 0.0266), however urokinase-type plasminogen
activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) showed no significant
difference between colon and rectal cancer tissues.
Conclusion: These findings suggest that uPA may be expressed differentially in colon and rectal
cancers, however, the activities or protein levels of MMP-2, MMP-9, TIMP-1, TIMP-2, PAI-1 and
uPAR are not affected by tumor location in the colon or the rectum.
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Background
Colorectal cancer, one of the most prevalent cancers
worldwide [1], is the second leading cause of cancer-
related mortality in developed countries [2]. Tumor cell
invasion and metastasis are regarded as multi-step phe-
nomena, involving the proteolytic degradation of the
basement membrane (BM) and the extracellular matrix
(ECM), altered cell adhesion, and the physical movement
of tumor cells. Among the many steps in invasion and
metastasis, excessive degradation of the matrix is one of
the hallmarks of this process [3].
Many proteinases are capable of degrading ECM compo-
nents, but the proteinase system primarily responsible for
ECM degradation in vivo are matrix metalloproteinase
(MMPs) and plasminogen activator (PA) systems [3,4].
These proteinases have been closely linked with the inva-
sive and metastatic phenotype of cancer cells [5,6].
MMP-2 and MMP-9 have been implicated to play a role in
colorectal cancer progression, invasion and metastasis in
animal models and patients [7]. The enzyme activity is
regulated extracellularly and its regulation is mainly based
on the balance between pro-enzyme activation and inhi-
bition by tissue inhibitors of MMPs (TIMPs) [8].
Urokinase plasminogen activator (uPA) is a 55 kDa serine
protease, which is secreted as an inactive pro-enzyme
(pro-uPA). It seems that activation of pro-uPA mostly
occurs after binding to its receptor uPAR (uPA receptor).
Plasminogen activator inhibitors (PAI-1 and PAI-2)
inhibit both receptor-bound and free uPA [9]. uPA is
found in cellular structures at the leading edge of migrat-
ing cells that are involved in adhesion, migration, inva-
sion, and intravasation [10]. The uPA system is considered
to be a marker for malignancy in several types of cancer
including colorectal cancer [11-13].
Observations support the theory that development of
colon and rectal cancers may involve different mecha-
nisms. Konishi et al. [14] reported that there may be some
mechanisms promote the progression of mucosal lesions
to invasive cancers in the left colon and rectum, whereas a
de novo pathway from depressed type lesions may be
implicated in some cancers of the right colon. Kapiteijn et
al. [15] found that rectal cancers showed significantly
more nuclear β-catenin and p53 expressions than colon
cancers. In addition, there was a report which shown
notable overexpression of COX-2 protein in tumors
located in the rectum compared with other locations in
the colon [16].
In terms of MMPs expressions in colorectal cancers, Lia-
bakk et al. [17] reported no significant difference in MMP-
2 and MMP-9 levels between tumors located in the colon
or the rectum. However, Roeb et al. [18] demonstrated
differences in MMP-9 activity between colon and rectal
cancers. These studies have looked at only the MMP sys-
tem. No previous study has determined the expression of
these two proteinase systems in the different sites of colon
and rectal cancer.
Therefore, we classified colorectal cancer into colon and
rectal cancer and examined differences in the expression
of MMP-2, MMP-9, TIMP-1, TIMP-2, uPA, uPAR and PAI-
1 between colon and rectal cancer.
Methods
Tissue samples
This study was approved by the Institutional Review
Boards of the Chungnam National University Hospital.
Tissue samples were obtained from sequential patients
during elective operations for colon (n = 12) and rectal (n
= 10) cancers. The resected specimens were washed with
cold saline. After removal of mucus with sterile gauze,
tumor tissue was excised and corresponding normal
colonic epithelial cell layer located at least 5 cm from the
tumor was scraped with sterile slide glass and collected.
All tissues were immediately frozen in liquid nitrogen and
then stored at -70°C until analysis.
Tissue homogenates
Frozen tumor tissue and normal mucosa were thawed and
homogenized in 100 mM Tris-HCl (pH 8.0) and 1% Tri-
ton X-100. Tissue homogenates were centrifuged at 1,500
g for 15 minutes to remove debris. Following clarification,
the homogenates were centrifuged at 100,000 g for 1 h at
4°C. Protein concentration of homogenates was deter-
mined for each sample using the Bradford method (Bio-
Rad, Hercules, CA) [19].
Analysis of MMP-2 and MMP-9 activities by gelatin 
zymography
Gelatinase activities of MMP-2 and MMP-9 in tissue
homogenates were examined by gelatin zymography. The
tissue homogenates (2 μg protein/lane) were separated by
electrophoresis in 10% polyacrylamide gel impregnated
with 1 mg/ml of gelatin (Fisher Chemical Co., Fair Lawn,
NJ) under nonreducing conditions. After electrophoresis,
the gels were washed twice in 2.5% Triton-X 100 for 30
min, incubated with reaction buffer (50 mM Tris-HCl, 5
mM CaCl2, and 0.02% NaN3, pH 8.0) for 18 h at 37°C,
and stained with Coomassie blue G-250. Conditioned
media of HT-1080, which have the highest baseline MMP-
9 and MMP-2 activities, were used as a positive control in
gelatin zymography. The Bio-Rad Gel-Doc system (Gel
Doc 2000™ Documentation System and QuantityOne-
software, Bio-Rad, Hercules, CA) was utilized to quantify
zymography band intensities. The relative activity of
MMP-2 and MMP-9 was expressed as the sum of the pro-BMC Cancer 2006, 6:211 http://www.biomedcentral.com/1471-2407/6/211
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enzyme and the active form, since active form was faintly
present in normal colon and rectal mucosa.
Analysis of uPA activities by casein-plasminogen 
zymography
Activities of uPA in tissue homogenates were examined by
casein-plasminogen zymography as previously described
[20]. The tissue homogenates (10 μg protein/lane) were
separated by electrophoresis in 10% polyacrylamide gel
copolymerized with 1 mg/ml of casein (Sigma, St. Louis,
MO) and 13 μg/ml human plasminogen (Sigma, St.
Louis, MO) under nonreducing conditions. After electro-
phoresis, the gels were washed twice in 2.5% Triton-X 100
for 30 min, incubated with reaction buffer (50 mM Tris-
HCl, 5 mM CaCl2, and 0.02% NaN3, pH 8.0) for 18 h at
37°C, and stained with Coomassie blue G-250. Condi-
tioned media of HT-1080, which have the highest base-
line uPA activities, were used as a positive control in
casein-plasminogen zymography.
Western blot analysis
Equal amounts of protein (100 μg) were loaded in each
lane and separated by 10–15% SDS-PAGE. The proteins
were transferred to PVDF membranes (Millipore, Billerica,
MA). The membranes were blocked with 5% skim milk in
TBS containing 0.1% Tween 20, and then incubated at
room temperature for 3 h in the presence of each antibody
(mouse monoclonal anti-human MMP-2 obtained from
Oncogene, Boston, MA, mouse monoclonal anti-human
MMP-9, anti-human TIMP-1 and anti-human TIMP-2
obtained from Neomarkers, Fremont, CA). The mem-
brane was washed three times with 0.1% Tween 20 in PBS
and stained with horseradish peroxidase-conjugated sec-
ondary antibodies. The ECL system (Amersham Life Sci-
ence, Buckinghamshire, UK) was used for detection [21].
The intensities of immunoreactive bands were measured
by computerized image analysis (QuantityOne-software,
Bio-Rad, Hercules, CA) and normalized to actin as the
internal control.
uPA, uPAR andPAI-1 concentrations by ELISA assay
Biochemical analyses of uPA, uPAR, and PAI-1 were per-
formed using the sandwich ELISA which employs murine
monoclonal anti-human uPA, rabbit polyclonal anti-
human uPAR or anti-human PAI-1 antibodies coated on
96-well plates (IMUBIND, American Diagnostica Inc.,
Greenwich, CT). The uPA assay recognizes pro-uPA, high
molecular-weight uPA, receptor-bound uPA and uPA
complexed with PAI-1 and PAI-2. With the uPAR assay,
both soluble and native (membrane-associated) uPAR as
well as complexes of either uPAR/uPA or uPAR/uPA/PAI-
1 are all recognized. The PAI-1 assay determines both
active and inactive forms of free PAI-1 and PAI-1 com-
plexes. Extracts were diluted 1:20 in assay buffer, and 100
μl aliquots of each extract were incubated overnight at
4°C in precoated microtest wells. Wells were washed thor-
oughly using wash buffer, and a secondary biotinylated
antibody that recognizes a specific epitope on uPA, uPAR,
or PAI-1 molecules was added for each analysis. Wells
were washed again after an incubation of 1 h, and 100 μl
of enzyme conjugate was added (streptavidin-conjugated
horseradish peroxidase), leading to the formation of the
antibody-enzyme detection complex. After a 1 h incuba-
tion, wells were washed again. Then 100 μl of perborate 3,
3', 5, 5'-tetramethylbenzidine substrate was added to each
well and reacted with horseradish peroxidase, producing
a blue solution. Sulfuric acid (0.5 M) was used as a stop-
ping solution, which yielded a yellow color in the reac-
tion. The levels of uPA, uPAR, and PAI-1 were quantified
by measuring the absorbance at 450 nm, using a micro-
plate reader and interpolating them with absorbance of
the standard curve. The final concentration was expressed
in ng of uPA, uPAR, and PAI-1 per mg extract protein.
Statistical analysis
Statistical analyses were performed using the The Graph-
pad Instat version 3.05 software program (Graphpad Soft-
ware, Inc, San Diego, CA). Significance of difference
between values was assessed using paired t-test and all val-
ues were expressed as mean ± SE. Statistical significance
was assigned when P < 0.05.
Results and discussion
Patients characteristics
The patient's age, sex, tumor stage, differentiation and
lymphovascular invasion status were summarized in
Table 1.
Activities of MMP-2 and MMP-9
Zymographic detection on substrate gels is often a good
choice for the initial characterization of a proteinase activ-
ity. This technique permits important information, such
as estimated molecular weight and proteinase class, to be
obtained. In addition, it circumvents two common prob-
lems encountered in the assay: (a) Many proenzymes
show activity when assayed in this manner, thus eliminat-
ing the requirement for activation. (b) Electrophoresis can
result in the separation of non-covalent proteinase-inhib-
itor complexes. We performed gelatin zymography for the
initial characterization of MMP-2 and MMP-9 in tumors
and their corresponding normal mucosa from colon and
rectal cancer patients (Figure 1). After zymography, four
gelatinolytic bands which inhibited with MMPs inhibitor,
1,10-phenanthroline could be observed, with molecular
masses of 92 kDa (latent MMP-9), 84 kDa (active MMP-
9), 72 kDa (latent MMP-2), and 62 kDa (active MMP-2).
(Figure 1a,b). Computer assisted image analysis of the
intensity of the proteolytic bands showed that the levels of
MMP-2 and MMP-9 activity in colorectal cancer tissues
were higher than those in normal tissues in all samplesBMC Cancer 2006, 6:211 http://www.biomedcentral.com/1471-2407/6/211
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(22/22). The increase in MMP-2 and MMP-9 activity was
3.3-fold (P = 0.0002) and 5.8-fold (P = 0.0042) in colon
cancer tissue compared with normal colonic mucosa,
respectively (Figure 1c). In rectal cancer tissue, the levels
of MMP-2 and MMP-9 activity were 3.5-fold (P < 0.0001)
and 4.5-fold (P = 0.0006) higher than in normal mucosa,
respectively (Figure 1c). Roeb et al. [18] reported that in
colon tumors, MMP-9 activity was increased significantly
compared with normal tissue, but in rectal tumors there
were no significant differences in MMP-9 levels between
tumors and normal tissues, showing a difference between
tumors located in colon and rectum. However, in our
zymography results, the levels of MMP-2 and MMP-9
activity were increased in the rectal cancer tissues as well
as in the colon cancer tissues. Furthermore, no significant
difference of the increase of either MMP-2 or MMP-9
activity was found between colon and rectal cancer tissues
(MMP-2, P = 0.9815; MMP-9, P = 0.7979; Figure 1c).
Protein expression of MMP-2 and MMP-9
To further investigate the difference in protein levels of
MMP-2 and MMP-9, Western blotting was used. A single
band was found at 72 kDa for MMP-2 and at 92 kDa for
MMP-9 in each sample (Figure 2a,b). Image analysis of
the intensity of the bands showed that the increase in
MMP-2 and MMP-9 was 1.8-fold (P = 0.0041) and 2.9-
fold (P = 0.0175), respectively, in colon cancer tissue com-
pared with normal colonic mucosa (Figure 2c). In rectal
cancer tissue, the levels of MMP-2 and MMP-9 were 2.0-
fold (P = 0.0477) and 1.8-fold (P = 0.0219) higher than in
normal mucosa, respectively (Figure 2c). Furthermore,
consistent with results obtained by previous zymographic
analyses (Figure 1), no significant difference in the
increase of MMP-2 protein expression was found between
colon cancer and rectal cancer tissue (P = 0.7383; Figure
2c, left panel). There was a trend toward higher MMP-9
expression in colon tumors than in rectal tumors when
compared to the corresponding paired adjacent normal
tissues, but the difference was not statistically significant
(P = 0.1747, Figure 2c, right panel). These results suggest
that MMP-2 and MMP-9 are expressed increasingly in
equal amount and activity regardless of tumor location in
colon and rectum compared with corresponding normal
mucosa.
Protein expression of TIMP-1 and TIMP-2
MMP enzyme activity is regulated at multiple levels,
including activation of the latent precursor, gene tran-
scription, and specific inhibition by naturally occurring
tissue inhibitors [8]. To determine the expression of the
endogenous inhibitors of MMP-2 and MMP-9 in colon
and rectal cancer tissues, we examined the protein expres-
sion of TIMP-2 and TIMP-1 by Western blot (Figure 3).
TIMP-1 immunoreactive band (30 kDa) was identified in
all normal mucosa samples and its intensity seemed to be
increased in both cancer tissues, on the other hand, TIMP-
2 immunoreactivity (21 kDa) was detected in 100% of
normal mucosa regardless of tumor location and was
hardly detected or absent in colon (83.3%) and rectal
(100%) cancer tissues. (Representative data shown in Fig-
ure 3a,b). Image analysis showed that TIMP-1 levels
seemed to be higher in the colon cancer tissues (1.82 ±
0.32-fold, P = 0.0729) and were significantly higher in the
rectal cancer tissues (1.64 ± 0.23-fold, P = 0.0477) than in
the corresponding normal mucosa (Figure 3c, left panel).
Upregulated TIMP-1 expression in cancer tissues, includ-
ing colorectal cancer, was observed in other reports
[22,23]. Thus, upregulation of TIMP-1 in cancer tissue
may be a common feature in human cancer. In contrast,
TIMP-2 expression in colon and rectal cancer tissues was
significantly lower than in corresponding normal mucosa
(38.84%, P = 0.0008; 33.82%, P = 0.0004, respectively)
(Figure 3c, right panel). It was reported that TIMP-2 was
regulated independently of TIMP-1, both in cell culture
and in vivo [24]. Previously published studies reported
that the expression level of TIMP-2 in colorectal carci-
noma tissues was much lower than that in normal tissues
[23,25]. Our data confirm the down-regulation of TIMP-2
in colorectal cancer as compared to normal tissue. Moreo-
ver, we found no significant difference between colon and
Table 1: Patient characteristics
Mean age (range) Sexb (n) Location (n) Dukes' stage (n) Differentiationa (n) V/Lc (n)
Colon 64.0 (48–81) m (7) Caecum (5) B (4) moder. diff (8) +/+ (12)
Sigmoid (5) C (7)
f (5) Transverse (2) D (1) poorly diff (4)
Rectum 68.2 (53–76) m (7) (10) A (2) moder. diff (10) +/+ (10)
B (4)
f (3) C (4) poorly diff (0)
a moder. diff = moderate differentiation, poorly diff = poorly differentiation
b m = male, f = female
c V/L = vascular invasion/lymphatic invasionBMC Cancer 2006, 6:211 http://www.biomedcentral.com/1471-2407/6/211
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MMP-2 and MMP-9 activities analyzed by gelatinzymography Figure 1
MMP-2 and MMP-9 activities analyzed by gelatinzymography. (a) Gelatin zymography of 4 representative specimens 
of colon tumor (CT) and the corresponding paired adjacent normal colonic mucosa (CN) from colon cancer patients. (b) Gel-
atin zymography of 4 representative specimens of rectal tumor (RT) and the corresponding paired adjacent normal rectal 
mucosa (RN) from rectal cancer patients. (c) Zymographic band densities from all tissue samples were quantified by densitom-
etry. The relative enzyme activities of MMP-2 and MMP-9 are expressed as a mean ± SE. ns, non-significant. **P < 0.01. ***P < 
0.001
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The expression of MMP-2 and MMP-9 in tumor tissuesand adjacent normal mucosa of colon and rectal cancer patients Figure 2
The expression of MMP-2 and MMP-9 in tumor tissuesand adjacent normal mucosa of colon and rectal cancer 
patients. (a) Representative Western blot analysis of colon tumor (CT) and the corresponding paired adjacent normal colonic 
mucosa (CN) from colon cancer patients. (b) Representative Western blots of rectal tumor (RT) and the corresponding paired 
adjacent normal rectal mucosa (RN) from rectal cancer patients. (c) Band densities from all tissue samples were quantified and 
the relative expression of MMP-2 and MMP-9 are expressed as a mean ± SE. ns, non-significant. *P < 0.05. **P < 0.01.
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The expression of TIMP-1 and TIMP-2 in tumortissues and adjacent normal mucosa of colon and rectal cancer patients Figure 3
The expression of TIMP-1 and TIMP-2 in tumortissues and adjacent normal mucosa of colon and rectal cancer 
patients. (a) Representative Western blot analysis of colon tumor (CT) and the corresponding paired adjacent normal colonic 
mucosa (CN) from colon cancer patients. (b) Representative Western blots of rectal tumor (RT) and the corresponding paired 
adjacent normal rectal mucosa (RN) from rectal cancer patients. (c) Band densities from all tissue samples were quantified, and 
the relative expression of TIMP-1 and TIMP-2 are expressed as a mean ± SE. ns, non-significant. *P < 0.05. ***P < 0.001.
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rectal cancer tissues in terms of the expression of TIMP-1
(P = 0.7873) and TIMP-2 (P = 0.6802) (Fig. 3c).
Activity and protein expression of uPA
Casein-substrate gels copolymerized with plasminogen
were used to characterize uPA activity present in tumor tis-
sues and corresponding normal tissues. As shown in Fig-
ure 4a, a lysis band corresponding to a molecular weight
of approximately 55 kDa was identified as uPA in tumor
lysates; however, very little or no activity was detected in
normal mucosa. Furthermore, the increase in the activity
of uPA in colon cancer tissues compared with normal
mucosa was lower than that of rectal cancer.
To further evaluate uPA expression, ELISA was performed.
uPA levels in colon cancer and rectal cancer tissues
(median value: 2.57 ± 0.27 ng/mg protein, 3.08 ± 0.42 ng/
mg protein; range: 1.15–3.63 ng/mg protein, 0.41–5.02
ng/mg protein, respectively) were significantly higher
than that of corresponding normal mucosa (median
value: 0.44 ± 0.043 ng/mg protein, 0.31 ± 0.044 ng/mg
protein; range: 0.21–0.66 ng/mg protein, 0.11–0.58 ng/
mg protein, respectively) (P < 0.001) and found to be ele-
vated in 100% (22/22) of colorectal cancer tissues, when
compared with corresponding normal mucosa (Figure
4b). The levels of uPA were increased in colon tumor tis-
sues (6.42-fold), as well as in rectal tumor tissues (10.78-
fold), compared with corresponding normal mucosa (Fig-
ure 4c). Furthermore, there was a statistically significant
difference in the increasing rate of uPA protein between
colon and rectal cancers (P = 0.0266) (Figure 4c, right
panel).
Upregulated uPA levels appear to be an important nega-
tive prognostic indicator in colorectal cancer [9]. A previ-
ous study suggested that the stromal cells were
responsible for the increased uPA [26]. However, other
studies demonstrated production of uPA only by the can-
cerous epithelial cells [27,28]. It appears that there are
multiple pathways present in the cancerous epithelial cell
that lead to overproduction of uPA [29]. It has been sug-
gested that the NF-kB activation pathway [30] and
cyclooxygenase-2 (COX-2) [31] lead to increased uPA
production. In addition, Dimberg et al. [16] reported that
the enhanced COX-2 protein levels were localized more
preferentially to rectal tumors than colon tumors. In the
present study, we found that there was significant differ-
ence in uPA protein levels between colon and rectal cancer
tissues. The explanation and interpretation of this finding
is still uncertain but may be due to differences in uPA reg-
ulatory genes and/or differences in molecules such as
COX-2 in the colon and rectal cancer tissues.
Protein expression of uPAR and PAI-1
ELISA analysis was used to investigate the protein expres-
sion of uPAR and PAI-1 (Figure 5). uPAR and PAI-1 levels
of colon cancer (median value: 8.72 ± 0.97 ng/mg protein,
2.35 ± 1.011 ng/mg protein; range: 5.10–13.38 ng/mg
protein, 0.42–12.76 ng/mg protein, respectively) and rec-
tal cancer tissues (median value: 8.38 ± 0.94 ng/mg pro-
tein, 2.99 ± 0.99 ng/mg protein; range: 4.06–14.33 ng/mg
protein, 0.495–11.31 ng/mg protein, respectively) were
significantly higher (P < 0.01) than that of normal colonic
mucosa (median value: 2.61 ± 0.23 ng/mg protein, 0.25 ±
0.029 ng/mg protein, respectively; range: 1.43–3.78 ng/
mg protein, 0.07–0.38 ng/mg protein, respectively) and
normal rectal mucosa (median value: 2.96 ± 0.41 ng/mg
protein, 0.26 ± 0.053 ng/mg protein, respectively; range:
1.85–5.36 ng/mg protein, 0.05–0.57 ng/mg protein,
respectively) and these proteins were found to be elevated
in 100% (22/22) of colon and rectal cancer tissues, when
compared with corresponding paired normal mucosa
(Figure 5a,b, left panels). The levels of uPAR and PAI-1
were increased in colon cancer (3.56-fold, 10.08-fold,
respectively) and rectal cancer (3.19-fold, 12.90-fold,
respectively), compared with normal mucosa (Figure
5a,b, right panels). However, the increase in uPAR and
PAI-1 levels did not reach a statistically significant differ-
ence between colon and rectal cancer (uPAR, P = 0.6207;
PAI-1, P = 0.5781).
The functional role of PAI-1 in cancer tissue is unknown.
Recently, it was reported that the increase of PAI-1 expres-
sion was observed in node-positive and metastatic cancers
compared with node-negative and metastasis-negative
cancers [32]. The upregulated PAI-1 in malignant tumor
may play a role in protecting the tumor tissue against the
destruction of uPA, in reimplantation of circulating tumor
cells, and in promoting angiogenesis [12].
The number of patients in this study was quite small to
reveal the significance of statistical analysis between each
tumor status and various enzymes with related proteins
we have studied. No association among the activity or
protein expression of MMP-2, MMP-9, TIMP-1, TIMP-2,
uPA, uPAR and PAI-1, and patient Dukes' stage, cellular
differentiation, or lymphovascular invasion status was
found.
Conclusion
In summary, the present study indicates that the activities
or protein levels of MMP-2, MMP-9, TIMP-1, TIMP-2,
uPAR and PAI-1 do not differ between tumors located in
the colon or rectum. However, uPA may be expressed dif-
ferentially in colon and rectal cancer.BMC Cancer 2006, 6:211 http://www.biomedcentral.com/1471-2407/6/211
Page 9 of 11
(page number not for citation purposes)
Activity and expression of uPA in tumor tissues andadjacent normal mucosaof colon and rectal cancer patients Figure 4
Activity and expression of uPA in tumor tissues andadjacent normal mucosaof colon and rectal cancer 
patients. (a) Casein-plasminogen zymography of representative specimens of colon tumor (CT) and the corresponding paired 
adjacent normal colonic mucosa (CN) from colon cancer patients, and rectal tumor (RT) and the corresponding paired adja-
cent normal rectal mucosa (RN) from rectal cancer patients. (b) Concentration of uPA in tumor tissues and adjacent normal 
colonic mucosa of colon and rectal cancer patients determined by ELISA. (c) Mean concentration (left panel) and fold increase 
(right panel) of uPA in tumor tissues compared with normal tissues. uPA levels are significantly increased in rectal cancer 
patients compared with colon cancer patients. *P < 0.05. ***P < 0.001.
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